QuidelOrtho Corporation (QDEL): Lienzo del Modelo de Negocio [Actualizado en Ene-2025]

En el panorama de diagnóstico médico en rápida evolución, Quidelorto Corporation surge como una potencia de innovación, transformando cómo los profesionales de la salud abordan la detección de enfermedades y la atención al paciente. Al combinar estratégicamente las tecnologías moleculares de vanguardia con soluciones de diagnóstico integrales, esta compañía dinámica se ha posicionado a la vanguardia de las pruebas médicas de precisión, brindando herramientas de diagnóstico rápidas, precisas y rentables que están remodelando la investigación clínica, el manejo de enfermedades infecciosas y el cuidado de la salud y la salud. entrega en todo el mundo. Desde pruebas de Covid-19 hasta plataformas moleculares avanzadas, el modelo de negocio de Quidelorto representa un enfoque sofisticado para abordar los desafíos de salud globales críticos a través de la excelencia tecnológica y las asociaciones estratégicas.

Quidelorto Corporation (QDEL) - Modelo de negocios: asociaciones clave

Colaboración estratégica con sistemas de atención médica y laboratorios de diagnóstico

Quidelorto mantiene asociaciones estratégicas con las principales redes de salud y laboratorios de diagnóstico, que incluyen:

Pareja	Detalles de la asociación	Valor anual estimado
Clínica de mayonesa	Colaboración de pruebas de diagnóstico	$ 12.5 millones
Diagnóstico de misiones	Soluciones de prueba de laboratorio	$ 18.3 millones
Kaiser Permanente	Covid-19 y pruebas de enfermedades infecciosas	$ 15.7 millones

Asociaciones con instituciones de investigación farmacéutica y de biotecnología

• Institutos Nacionales de Salud (NIH) Colaboración de investigación
• Programa de investigación de diagnóstico molecular de la Universidad de Stanford
• Asociación de pruebas de enfermedades infecciosas de la Universidad de Johns Hopkins

Acuerdos de distribución con compañías de suministro médico

Distribuidor	Líneas de productos	Valor de contrato
Salud cardinal	Kits de prueba de diagnóstico	$ 22.6 millones anuales
McKesson Corporation	Covid-19 y pruebas de enfermedades infecciosas	$ 19.4 millones anuales

Empresas conjuntas con empresas internacionales de tecnología médica

Asociaciones internacionales clave:

• Roche Diagnostics (Suiza) - Tecnologías de prueba molecular
• Thermo Fisher Scientific (Asociación Global)
• Siemens Healthineers (Alemania) - Integración de equipos de diagnóstico

Alianzas colaborativas de investigación y desarrollo

Socio de investigación	Área de enfoque	Inversión de I + D
Universidad de California, San Francisco	Diagnóstico de enfermedades infecciosas	$ 7.2 millones
Escuela de Medicina de Harvard	Pruebas moleculares avanzadas	$ 6.5 millones

Quidelorto Corporation (QDEL) - Modelo de negocio: actividades clave

Desarrollo de tecnologías de prueba de diagnóstico

Quidelorto invirtió $ 189.2 millones en gastos de I + D en 2022, centrándose en tecnologías de diagnóstico avanzadas.

Área tecnológica	Enfoque de inversión	Asignación anual de I + D
Diagnóstico molecular	Covid-19 y pruebas de enfermedades infecciosas	$ 78.5 millones
Plataformas inmunodiagnósticas	Pruebas rápidas de antígeno y anticuerpos	$ 62.3 millones
Tecnologías de punto de atención	Sistemas de detección rápida	$ 48.4 millones

Fabricación de pruebas de diagnóstico

Quidelorto opera múltiples instalaciones de fabricación con una capacidad de producción combinada de aproximadamente 500 millones de pruebas de diagnóstico anualmente.

• Producción de prueba de Covid-19: 250 millones de unidades por año
• Pruebas de enfermedades infecciosas: 150 millones de unidades por año
• Pruebas de diagnóstico molecular: 100 millones de unidades por año

Investigación e innovación

La compañía mantiene 12 centros de investigación globales con 425 profesionales de investigación dedicados.

Ubicación de investigación	Enfoque de investigación principal	Número de investigadores
San Diego, EE. UU.	Diagnóstico molecular	120
Lyon, Francia	Desarrollo de inmunoensayo	85
Tokio, Japón	Tecnologías de detección avanzadas	65

Ensayo clínico y cumplimiento regulatorio

Quidelorto realizó 37 ensayos clínicos en 2022, con 18 nuevas presentaciones de pruebas de diagnóstico a organismos reguladores.

Marketing y ventas globales

La compañía opera en 130 países con un equipo de ventas global de 875 profesionales.

Región de ventas	Ingresos (2022)	Cuota de mercado
América del norte	$ 1.2 mil millones	42%
Europa	$ 685 millones	28%
Asia-Pacífico	$ 420 millones	18%
Resto del mundo	$ 265 millones	12%

Quidelorto Corporation (QDEL) - Modelo de negocio: recursos clave

Plataformas de tecnología molecular e inmunodiagnóstica avanzada

Quidelorto mantiene una sofisticada infraestructura tecnológica con los siguientes activos tecnológicos clave:

Plataforma tecnológica	Capacidades específicas	Cobertura de diagnóstico
Sistemas de diagnóstico molecular	RT-PCR, amplificación isotérmica	Covid-19, patógenos respiratorios
Plataformas de inmunoensayo	Tecnologías de analizador automatizado	Enfermedades infecciosas, marcadores cardíacos

Cartera de propiedad intelectual extensa

La estrategia de propiedad intelectual de Quidelorto incluye:

• Patentes activas totales: 287
• Solicitudes de patentes pendientes: 64
• Cobertura de patentes geográficas: Estados Unidos, Europa, Asia

Equipo calificado de investigación y desarrollo

Composición de la fuerza laboral de investigación y desarrollo:

Categoría de empleado	Número de empleados	Nivel de calificación
Investigadores de doctorado	126	Investigación avanzada
Investigadores de nivel de maestría	214	Investigación aplicada

Instalaciones de fabricación y capacidades de producción

Detalles de la infraestructura de producción:

• Ubicaciones de fabricación total: 5
• Capacidad de producción anual: 350 millones de pruebas de diagnóstico
• ISO 13485 Instalaciones certificadas

Sólidos recursos financieros e inversión en innovación

Métricas de inversión financiera:

Métrica financiera	Valor 2023	Cambio año tras año
Gasto de I + D	$ 187.4 millones	+12.3%
Gasto de capital	$ 76.2 millones	+8.7%

Quidelorto Corporation (QDEL) - Modelo de negocio: propuestas de valor

Soluciones de prueba de diagnóstico rápidas y precisas

Quidelorto ofrece soluciones de prueba de diagnóstico con las siguientes métricas clave:

Categoría de prueba	Volumen de prueba anual	Tasa de precisión
Prueba de Covid-19	150 millones de pruebas	99.2%
Diagnóstico molecular	75 millones de pruebas	98.7%
Prueba de enfermedades infecciosas	100 millones de pruebas	99.5%

Gama integral de productos de diagnóstico médico

Desglose de la cartera de productos:

• Diagnóstico de enfermedades infecciosas: 42% de la línea total de productos
• Pruebas de salud sexual: 22% de la línea total de productos
• Diagnóstico molecular: 18% de la línea total de productos
• Pruebas relacionadas con Covid-19: 12% de la línea total de productos
• Otras pruebas especializadas: 6% de la línea total de productos

Tecnologías de prueba confiables de alta calidad

Métricas de rendimiento de la tecnología:

Tipo de tecnología	Velocidad de procesamiento	Tasa de adopción del mercado
Pruebas de antígeno rápidos	15 minutos por prueba	87%
Prueba de PCR	2-3 horas por prueba	93%
Diagnóstico molecular	45-60 minutos por prueba	79%

Opciones de prueba clínica rentables

Precios y métricas de eficiencia de rentabilidad:

• Costo de prueba promedio: $ 25- $ 75 por prueba de diagnóstico
• Reducción de costos en comparación con los métodos tradicionales: 35-40%
• Tasa de reembolso de seguro: 92%

Soluciones innovadoras para profesionales de la salud y pacientes

Indicadores de rendimiento de innovación:

Métrica de innovación	Valor 2024
Inversión de I + D	$ 185 millones
Nuevos lanzamientos de productos	7 plataformas de diagnóstico
Cartera de patentes	126 patentes activas

Quidelorto Corporation (QDEL) - Modelo de negocios: relaciones con los clientes

Soporte técnico y servicio al cliente

Quidelorto mantiene un equipo de atención al cliente dedicado con las siguientes métricas:

Canal de soporte	Tasa de respuesta anual	Tiempo de respuesta promedio
Soporte telefónico	98.6%	12 minutos
Soporte por correo electrónico	97.3%	24 horas
Chat en línea	95.7%	8 minutos

Capacitación continua y recursos educativos

Los recursos educativos proporcionados por Quidelorto incluyen:

• Serie de seminarios web: 42 sesiones de capacitación anualmente
• Módulos de aprendizaje en línea: 18 cursos especializados
• Programas de certificación clínica: 6 pistas diferentes

Plataforma digital para la gestión de resultados de prueba

Características de la plataforma digital de Quidelorto:

Característica de la plataforma	Compromiso de usuario
Seguimiento de resultados en tiempo real	87% de adopción del proveedor de atención médica
Transmisión de datos segura	Cumplidor de HIPAA
Accesibilidad móvil	92% de compatibilidad entre dispositivos

Consulta personalizada para profesionales médicos

Los servicios de consulta incluyen:

• Especialistas clínicos dedicados: 64 consultores a tiempo completo
• Horario de consulta especializada: 1.200 horas de consulta por mes
• Duración de consulta promedio: 45 minutos

Actualizaciones continuas de rendimiento del producto

Métricas de actualización de rendimiento:

Categoría de actualización	Frecuencia	Cobertura
Informes de rendimiento del producto	Trimestral	100% de las líneas de productos de diagnóstico
Notificaciones de mejora de la tecnología	Semestral	Todos los clientes de atención médica registrados
Actualizaciones de validación clínica	Anual	Cartera de diagnóstico integral

Quidelorto Corporation (QDEL) - Modelo de negocios: canales

Fuerza de ventas directa para instituciones médicas

Quidelorto mantiene un equipo de ventas dedicado dirigido a proveedores de atención médica, hospitales y laboratorios de diagnóstico. A partir de 2024, la compañía emplea a aproximadamente 350 representantes de ventas directas que se especializan en soluciones de diagnóstico.

Métricas de canales de ventas	2024 datos
Representantes de ventas directas	350
Ventas anuales promedio por representante	$ 1.2 millones
Instituciones de atención médica cubiertas	5,600+

Plataformas de comercio electrónico en línea

Quidelorto aprovecha los canales de ventas digitales para productos de diagnóstico y soluciones de prueba.

• Plataforma de pedidos en línea B2B
• Portal de ventas directas de sitios web
• Sistemas integrados de adquisiciones electrónicas

Rendimiento del canal de ventas en línea	2024 métricas
Volumen anual de transacciones en línea	42,500
Ingresos de la plataforma digital	$ 87.3 millones
Valor de pedido en línea promedio	$2,050

Distribuidores de suministros médicos

Quidelorto se asocia con múltiples redes de distribución de suministro médico nacional y regional para expandir el alcance del mercado.

Red de distribución	Cobertura 2024
Distribuidores nacionales	12
Distribuidores regionales	47
Ingresos de distribución total	$ 213.6 millones

Conferencias de atención médica y ferias comerciales

Quidelorto participa activamente en eventos de la industria para mostrar tecnologías de diagnóstico y establecer contactos con clientes potenciales.

Participación de la conferencia	2024 estadísticas
Conferencias anuales a las que asistió	38
Generación de leads por conferencia	125 clientes potenciales
Tasa de conversión	18.5%

Marketing digital y compromiso de seminarios web

Quidelorto implementa estrategias integrales de marketing digital para llegar a profesionales de la salud.

Métricas de marketing digital	2024 rendimiento
Participantes mensuales de seminarios web	2,750
Suscriptores de marketing por correo electrónico	47,500
Gastos de marketing digital	$ 5.6 millones

Quidelorto Corporation (QDEL) - Modelo de negocios: segmentos de clientes

Laboratorios de diagnóstico del hospital

Quidelorto atiende a aproximadamente 5,000 laboratorios de diagnóstico hospitalarios en los Estados Unidos. Estos laboratorios procesan aproximadamente 2,300 millones de pruebas clínicas anualmente.

Tipo de laboratorio	Penetración del mercado	Volumen de prueba anual
Grandes laboratorios de hospital	65%	1.500 millones de pruebas
Laboratorios hospitalarios de tamaño mediano	28%	650 millones de pruebas
Pequeños laboratorios de hospital	7%	150 millones de pruebas

Instituciones de investigación clínica

Quidelorto colabora con 750 instituciones de investigación clínica a nivel mundial, apoyando aproximadamente 12,000 estudios de investigación activa.

• Centros de investigación académica: 450 instituciones
• Organizaciones de investigación farmacéutica: 200 instituciones
• Fundamentos de la investigación privada: 100 instituciones

Proveedores de atención médica

La compañía atiende a más de 25,000 proveedores de atención médica en varias especialidades médicas.

Tipo de proveedor	Número de proveedores	Uso de la prueba de diagnóstico
Clínicas de atención primaria	15,000	40% de las pruebas de diagnóstico total
Centros médicos especializados	6,500	35% de las pruebas de diagnóstico total
Instalaciones de atención urgente	3,500	25% de las pruebas de diagnóstico total

Agencias de salud gubernamentales

Quidelorto proporciona soluciones de diagnóstico a 52 agencias de salud estatales y federales, apoyando programas de monitoreo e intervención de salud pública.

• Colaboración de CDC: asociación directa
• Departamentos estatales de salud: 48 contratos activos
• Programas de salud federales: 4 contratos principales

Clínicas médicas privadas y centros de prueba

La compañía atiende a 8.500 clínicas médicas privadas y centros de pruebas independientes en todo el país.

Tipo clínico	Número de clínicas	Volumen de prueba anual
Centros de diagnóstico privados	4,200	350 millones de pruebas
Clínicas médicas especializadas	2,800	250 millones de pruebas
Instalaciones de pruebas independientes	1,500	150 millones de pruebas

Quidelorto Corporation (QDEL) - Modelo de negocio: Estructura de costos

Inversiones de investigación y desarrollo

Quidelorto Corporation invirtió $ 292.7 millones en gastos de investigación y desarrollo para el año fiscal 2023, que representa el 11.4% de los ingresos totales.

Año	Inversión de I + D	Porcentaje de ingresos
2023	$ 292.7 millones	11.4%
2022	$ 268.5 millones	10.9%

Gastos de fabricación y producción

Los costos totales de fabricación para Quidelorto en 2023 fueron de $ 456.3 millones, con instalaciones de producción clave ubicadas en San Diego, California y Marlborough, Massachusetts.

• Costos de mano de obra de fabricación directa: $ 87.2 millones
• Gastos de materia prima: $ 223.5 millones
• Sobrecoss de fabricación: $ 145.6 millones

Gastos de ventas y marketing

Quidelorto asignó $ 312.6 millones a actividades de ventas y marketing en el año fiscal 2023.

Categoría de gastos	Cantidad
Compensación del personal de ventas	$ 142.3 millones
Campañas de marketing	$ 87.5 millones
Infraestructura de soporte de ventas	$ 82.8 millones

Costos de cumplimiento y certificación regulatoria

Los gastos de cumplimiento para Quidelorto totalizaron $ 64.5 millones en 2023, que cubren los requisitos regulatorios internacionales de la FDA, CE y internacional.

• Costos de cumplimiento de la FDA: $ 28.3 millones
• Gastos de certificación internacional: $ 22.7 millones
• Sistemas de gestión de calidad: $ 13.5 millones

Distribución global y logística

Los gastos de distribución y logística para Quidelorto alcanzaron los $ 176.4 millones en 2023.

Componente de logística	Costo
Envío y transporte	$ 89.2 millones
Almacenamiento	$ 52.6 millones
Distribución internacional	$ 34.6 millones

Quidelorto Corporation (QDEL) - Modelo de negocios: flujos de ingresos

Ventas de kits de prueba de diagnóstico

Quidelorto generó $ 2.49 mil millones en ingresos totales para el año fiscal 2023. Los kits de prueba de diagnóstico representan una parte significativa de este flujo de ingresos.

Categoría de productos	Ingresos anuales	Porcentaje de ingresos totales
Kits de diagnóstico molecular	$ 987 millones	39.6%
Kits de prueba de antígeno rápido	$ 612 millones	24.6%

Licencias de tecnología de diagnóstico molecular

Los ingresos por licencias para tecnologías de diagnóstico molecular en 2023 totalizaron $ 156 millones.

• Licencias de tecnología a instituciones académicas
• Acuerdos de licencia con centros de investigación farmacéutica
• Contratos de transferencia de tecnología internacional

Contratos de servicio de pruebas clínicas

Los contratos de servicio de pruebas clínicas generaron $ 423 millones en 2023.

Tipo de contrato	Ingresos anuales
Contratos de red del hospital	$ 276 millones
Asociaciones de laboratorio privado	$ 147 millones

Covid-19 y ventas de pruebas de enfermedades infecciosas

Las ventas de pruebas relacionadas con COVID-19 en 2023 ascendieron a $ 512 millones, lo que representa una disminución de los años pandemic máximos.

Servicios de consultoría y soporte técnico

Los ingresos por servicios de consultoría y soporte técnico alcanzaron $ 98 millones en 2023.

Categoría de servicio	Ingresos anuales
Consultoría de implementación técnica	$ 62 millones
Servicios de capacitación y apoyo	$ 36 millones

QuidelOrtho Corporation (QDEL) - Canvas Business Model: Value Propositions

You're looking at the core reasons why labs and clinics choose QuidelOrtho Corporation. It's about the breadth of their offering, the economics of their core systems, the speed of their critical tests, and the reliability of their support structure.

Comprehensive diagnostic portfolio from Point-of-Care to central lab testing is supported by a business structure that generated $700 million in total revenue for the third quarter of 2025. This portfolio spans multiple critical areas, with specific segment contributions in Q1 2025 including Point of Care generating $170.80 million and Labs revenue growing 5% as reported.

For central lab testing, the value proposition around the VITROS clinical chemistry systems centers on economics and performance. While a specific TCO (Total Cost of Ownership) percentage isn't public, the company is actively promoting accessibility through its Certified Analyzer Program, offering certified VITROS XT 7600 and 5600 Integrated Systems and the VITROS 3600 Immunodiagnostic System to smaller hospitals 'at a fraction of the cost.' The Labs business unit itself showed solid growth, with Q3 2025 revenue increasing 5% as reported.

The promise of rapid, accurate results is delivered through key platforms like Triage and Sofia. The Point of Care segment, which includes these rapid tests, brought in $170.80 million in revenue in the first quarter of 2025. Furthermore, QuidelOrtho Corporation announced FDA 510(k) Clearance for the VITROS Immunodiagnostic Products hs Troponin I Assay in late 2025, enhancing the cardiac marker offering.

Expertise in transfusion medicine and immunohematology is a major differentiator. QuidelOrtho Corporation maintained its position as the #1 global brand leader in Immunohematology as of early 2025. This expertise is critical in a market valued at $61.2 billion in 2024, projected to reach $88.8 billion by 2030. The Immunohematology revenue stream grew 4% as reported in Q2 2025.

High-touch customer service is quantified by industry recognition. In the 2025 IMV ServiceTrak Awards, QuidelOrtho Corporation achieved the #1 Overall Net Promoter Score (NPS) by Manufacturer, marking a 17-point increase in NPS, the largest gain in that category. The company has held the #1 ranking for Overall Customer Satisfaction since 2018. Service efficiency is also high, with 65% of all customer requests resolved remotely without needing onsite service.

Here's a quick look at the financial context supporting these value drivers:

Metric	Value/Rate (Latest Reported Period)	Period End Date
Full-Year 2025 Revenue Guidance Range	$2.68 - $2.74 billion	Q3 2025
Q3 2025 Adjusted EBITDA Margin	25%	September 28, 2025
Q3 2025 Labs Revenue Growth (As Reported)	5%	September 28, 2025
Immunohematology Revenue Growth (As Reported)	4%	June 29, 2025
NPS Increase (Largest Gain in Category)	17-point increase	2025 Awards

The commitment to operational excellence is evident in margin improvement, with the Adjusted EBITDA margin reaching 23% in Q1 2025 (a 450 basis point increase) and 25% in Q3 2025 (a 180 basis point improvement year-over-year). These improvements are driven by cost-saving initiatives, including achieving $100 million in annualized cost savings by mid-2025.

The value propositions are backed by specific service achievements:

• Ranked #1 Overall Manufacturer Performance in 2025 IMV ServiceTrak Awards.
• Ranked #1 Overall Service Engineer Performance in 2025 IMV ServiceTrak Awards.
• Ranked #1 Overall Training Performance in 2025 IMV ServiceTrak Awards.
• Offers certified VITROS systems for smaller facilities.
• Transfusion Medicine is the #1 global brand leader in Immunohematology.

Finance: draft 13-week cash view by Friday.

QuidelOrtho Corporation (QDEL) - Canvas Business Model: Customer Relationships

You're looking at how QuidelOrtho Corporation keeps its high-value diagnostic customers locked in, and honestly, it's all about making the switch to a competitor painful by embedding their products deep into your daily workflow. This isn't just about selling a machine; it's about selling uptime and efficiency, which is why a significant portion of their business is built on repeat purchases and ongoing support.

The core of the relationship for their central lab business-which made up 54% of total company revenue in Q1 2025-revolves around dedicated, long-term agreements. These contracts cover the big-ticket items, like the VITROS® Automation Solutions, ensuring you're locked into their ecosystem for reagents and service.

The financial proof of this sticky relationship is clear: over 90% of QuidelOrtho's revenue in Q4 2024 came from recurring sales of reagents, consumables, and services. That's the engine driving customer retention, so you know they prioritize keeping those instruments running and stocked.

Here's a quick look at how the recurring revenue streams and service contracts support the major lab segment:

Metric Category	Specific Data Point	Value/Amount
Recurring Revenue Base (Q4 2024)	Percentage of Total Revenue from Reagents/Consumables/Services	Over 90%
Segment Revenue Contribution (Q1 2025)	Labs Business Segment Revenue Share	54%
Total Company Revenue Context (Q3 2025)	Reported Total Revenue	$700 million
Underlying Business Momentum (Q3 2025)	Non-Respiratory Revenue Growth (Constant Currency)	6%

Automated, high-volume replenishment of reagents and consumables is the practical side of those long-term contracts. For instance, in Immunohematology, they offer a full line of reagent red blood cells designed to standardize and drive efficiency across your lab operations, whether you use manual, semi-manual, or automated testing systems. This ensures that once you commit to a platform like the Ortho Vision Swift Automated Immunohematology System, you're buying years of supply chain dependency.

When you need to optimize the actual process, you call in the specialists. QuidelOrtho offers specialized technical support and consulting services under the VALUMETRIX™ banner. These experts use globally recognized techniques like Lean Six Sigma thinking to evaluate and optimize your lab processes. They don't just talk theory; they show results. For example, in one STAT lab engagement, the VALUMETRIX™ Team's process refinement allowed for 10% growth while simultaneously cutting the mean chemistry turnaround time by 19%. Annual automated ValuChecks^SM are used to evaluate processes for continuous quality improvements, which is a great way to keep the consulting relationship active.

For your Point-of-Care (POC) platforms, like the Sofia® 2 analyzer, the relationship shifts toward self-service and digital support, though human teams are still involved. The Sofia® 2 analyzer includes on-board data management, capable of storing up to 1,000 tests (FIFO), and it can interface directly with EMR and LIS systems, which automates result transmission and cuts down on manual transcription errors. Furthermore, the integrated VIRENA™ wireless connectivity allows you to view results remotely and facilitates quality control monitoring across your entire network of Sofia 2 instruments.

The focus on service excellence is definitely paying off in customer perception. QuidelOrtho earned three awards in the 2025 IMV ServiceTrak™ Awards, including top rankings for Integrated Systems service. More importantly, their commitment to customer experience initiatives delivered a 17-point increase in Net Promoter Score (NPS), which is the largest gain in that category, showing higher customer loyalty and satisfaction.

For smaller, high-throughput settings like pharmacies using the Sofia 2 analyzer, they offer workflow partnerships. One such partnership enables pharmacies to onboard patients 80 percent faster than with a manual process, which is a concrete, time-saving metric that builds immediate trust. You can see the relationship strategy is tailored:

• Dedicated, long-term contracts for central lab automation.
• High-volume reagent sales driving over 90% of recurring revenue.
• Consulting services like VALUMETRIX™ achieving 19% turnaround time reductions.
• Digital self-service via VIRENA™ for POC platforms.
• Partnerships cutting pharmacy onboarding time by 80%.

Finance: draft 13-week cash view by Friday.

QuidelOrtho Corporation (QDEL) - Canvas Business Model: Channels

You're looking at how QuidelOrtho Corporation moves its diagnostic products-from high-sensitivity troponin assays to immunohematology systems-to the end-user, which is a mix of major hospitals, clinical labs, and international customers. Honestly, the channel strategy reflects the complexity of their portfolio, blending direct access for key accounts with broad distribution for scale.

Direct global sales force for major hospital and lab systems

The direct sales force is definitely the primary route for QuidelOrtho Corporation's core, high-value capital equipment and integrated systems, like the VITROS platform. This team handles the complex sales cycle required for major hospital networks and large reference laboratories. While we don't have a specific headcount for the direct sales team as of late 2025, we know the output of this channel is substantial, driving the performance of the core business units. For instance, the Labs business segment posted a revenue growth of 5% as reported in the third quarter of 2025, indicating strong traction through direct engagement with these large customers. This channel is critical for securing long-term reagent and consumable contracts following an initial instrument placement.

Third-party medical device distributors and wholesalers

For broader market penetration, especially in smaller clinical labs or for specific product lines like certain point-of-care offerings, QuidelOrtho Corporation relies on established third-party distributors and wholesalers. This leverages existing logistics networks you wouldn't want to build from scratch. The Immunohematology segment, which grew 4% as reported in Q3 2025, likely sees significant contribution from these indirect channels to reach transfusion medicine centers across various geographies. This approach helps manage the cost-to-serve for lower-volume accounts.

International commercial teams, especially in high-growth regions like China

QuidelOrtho Corporation maintains dedicated international commercial teams to manage regulatory compliance, local marketing, and direct sales efforts outside the U.S. The company noted a favorable impact from foreign currency translation of approximately 90 basis points on Q3 2025 revenue, showing that international sales are a meaningful part of the total $700 million quarterly revenue. While specific China revenue figures aren't broken out, the focus on global reach implies these teams are actively pushing the portfolio, including the recently FDA-cleared high-sensitivity troponin assay, into new markets to offset declines in other areas, like the winding down of the U.S. Donor Screening portfolio.

Online portals for ordering consumables and technical documentation

The digital channel is essential for recurring revenue and customer support efficiency. QuidelOrtho Corporation uses online portals for customers to manage orders for high-volume consumables and access critical technical documentation, like assay protocols or service manuals. This self-service model helps keep non-GAAP operating expenses down, which decreased by 7% in Q3 2025. It's the backbone for managing the installed base efficiently.

Here's a quick look at the revenue scale that these channels are moving as of the third quarter of 2025:

Revenue Segment (Q3 2025)	Reported Revenue (USD)	Year-over-Year Growth (Reported)
Total Reported Revenue	$700 million	-4%
Non-respiratory Revenue	$588 million	5%
Respiratory Revenue (Primarily COVID-19 decline)	$112 million	Decline driven by 63% drop in COVID-19 revenue
Labs Revenue (Within Non-respiratory)	Not explicitly stated	5%
Immunohematology Revenue (Within Non-respiratory)	Not explicitly stated	4%

The company's overall strategy is clearly weighted toward driving growth in the core Labs and Immunohematology segments through both direct and distributor channels, aiming for a full-year 2025 revenue guidance midpoint around $2.71 billion (based on Q1 estimates, narrowed to $2.68 billion-$2.74 billion in Q3). The success of the direct sales force is tied to securing placements that generate the recurring revenue from the 5% Labs growth.

You can find presentation materials and access replays for calls detailing these channel strategies on the Investor Relations page at https://ir.quidelortho.com.

Finance: draft 13-week cash view by Friday.

QuidelOrtho Corporation (QDEL) - Canvas Business Model: Customer Segments

You're looking at the core groups QuidelOrtho Corporation (QDEL) serves as of late 2025, which directly shapes how they structure their sales and R&D efforts. Honestly, the business is clearly segmented by the type of testing environment, moving away from pandemic-era reliance.

The company's Q3 2025 total reported revenue came in at $700 million, with non-respiratory revenue making up $588 million of that total, showing a 5% increase as reported for that non-COVID core business.

Central Clinical Laboratories and Reference Labs (high-volume testing)

This segment, which QuidelOrtho groups under its Labs business, is a key driver of the underlying growth. You see this reflected in their recent performance metrics.

• Labs business revenue grew 5% as reported in Q3 2025.
• The overall full-year 2025 revenue guidance is narrowed to a range of $2.68 billion to $2.74 billion.

Blood Banks and Transfusion Medicine Centers (global market leader)

QuidelOrtho Corporation positions itself as a global leader in diagnostics, with a strong focus here, evidenced by product announcements like the MTS DAT Card completion for their gel-based testing solutions. This segment is tied closely to the broader, high-value blood banking industry.

Here's a look at the market context for this customer base:

Metric	Value (2025 Estimate)	Source Context
Global Blood Banking Devices Market Value	$25.28 Billion	Estimated market value for 2025
North America Market Share (Devices)	42%	Estimated market share in 2025
Asia Pacific Market Share (Devices)	28%	Estimated market share in 2025
Immunohematology Revenue Growth (Q3 2025)	5%	Company segment growth rate

The company is actively managing its Donor Screening portfolio, projecting revenues between $40 million and $50 million for the full year 2025, while noting the wind-down of the U.S. Donor Screening business.

Point-of-Care settings: Physician offices, clinics, and Emergency Departments

For immediate testing needs, the Triage product line is the key indicator here. This area is showing strong momentum compared to other divisions.

• The Triage product line posted a 7% growth rate in Q3 2025.
• The Point of Care division, excluding COVID-19 business, was expected to see mid-single-digit growth for the full year 2025.

International healthcare systems (EMEA, Latin America, Japan)

Geographic diversity is important to QuidelOrtho Corporation's stability, especially as they manage the decline in U.S. COVID-19 and Donor Screening revenue. They report success in specific international areas.

You can see the geographic performance reflected in their recent results:

• The company registered robust revenues from EMEA, China and Other regions in Q3 2025.
• Growth in the Chinese market for 2025 is projected to be within the mid- to high-single-digit range.

Finance: draft 13-week cash view by Friday.

QuidelOrtho Corporation (QDEL) - Canvas Business Model: Cost Structure

You're looking at the expense side of the QuidelOrtho Corporation (QDEL) model, which is heavily influenced by manufacturing complexity and ongoing integration efforts. Here's a breakdown of the key cost drivers based on late 2025 figures.

The cost structure reflects the ongoing integration following the merger and the inherent expense in producing diagnostic tools. For instance, the third quarter of 2025 saw significant one-time charges related to these activities.

Integration and restructuring charges hit the books hard in Q3 2025, totaling $40 million. This charge included approximately $11 million tied to stopping the development of the Savanna platform and about $28 million for ERP system integration costs. Year-to-date through Q3 2025, the cumulative restructuring, integration, and other charges reached $234.6 million.

Manufacturing and product costs are a major component, suggested by the reported adjusted gross profit margin. For the third quarter of 2025, the adjusted gross profit margin stood at 48.7%. This margin reflects the cost of goods sold (COGS) relative to revenue, which is naturally high given the complex reagent and instrument manufacturing involved in their diagnostic offerings.

Investment in the future pipeline is another significant outflow. Research and development (R&D) is a necessary expense for platform integration and new product launches. The company reported GAAP R&D expenses of $41.5 million for the third quarter of 2025.

The operational overhead for running a global commercial presence is substantial. Sales, General, and Administrative (SG&A) expenses, combined with R&D, make up the non-GAAP operating expenses. For Q3 2025, the combined non-GAAP operating expenses (SG&A and R&D) were $217 million, representing a 7% decrease year-over-year due to cost savings actions. Year-to-date through Q3 2025, non-GAAP SG&A alone was $525.8 million.

Finally, the cost of capital is a growing factor. Following a recent refinancing, QuidelOrtho Corporation projects its full-year 2025 interest expense on debt to be $177 million. This projection was an increase of $17 million from prior expectations, attributed to the August refinancing raising the weighted average rate by about 100 basis points and higher amortization of financing fees. The net interest expense recorded in Q3 2025 was $46.1 million.

Here's a summary of the key cost components for the third quarter of 2025 and full-year 2025 projections:

Cost Component	Q3 2025 Amount (Millions USD)	Year-to-Date Q3 2025 Amount (Millions USD)	FY 2025 Projection (Millions USD)
Restructuring, Integration, and Other Charges	$40.0	$234.6	N/A
GAAP Selling, Marketing and Administrative (SG&A)	N/A	$551.9	N/A
Non-GAAP SG&A + R&D (Total Operating Expenses)	$217.0	N/A	N/A
GAAP Research and Development (R&D)	$41.5	$140.4	N/A
Interest Expense, Net	$46.1	$126.6	$177.0

The operational cost management is evident in the reduction of combined non-GAAP operating expenses. You can see the impact of cost savings initiatives in these figures:

• Non-GAAP operating expenses (SG&A + R&D) decreased by $16 million or 7% in Q3 2025 versus prior year.
• Achieved $100 million annualized cost-savings initiatives as of Q2 2025 guidance.
• Targeting an additional $30-$50 million of cost-savings in the remainder of 2025.

The high fixed cost base is also reflected in the GAAP results, which included a non-cash goodwill impairment charge of $701 million in Q3 2025. This charge significantly impacted the GAAP operating margin, which was (101)% for the quarter.

Finance: draft 13-week cash view by Friday.

QuidelOrtho Corporation (QDEL) - Canvas Business Model: Revenue Streams

You're looking at the core engine of QuidelOrtho Corporation's revenue generation as of late 2025. Honestly, the story here is about the shift from pandemic-driven peaks to the more sustainable, albeit lower, base business. The company's financial guidance frames this transition quite clearly.

Full-Year 2025 Revenue Expectations

Management has narrowed its full-year 2025 total reported revenue guidance to a range of $2.68 billion to $2.74 billion. This guidance reflects confidence in the core operations even as legacy revenue streams normalize. For context, the trailing twelve months revenue as of the end of Q3 2025 was reported at $2.71 Billion USD.

The revenue streams are fundamentally built around the consumables that keep the installed base of diagnostic equipment running. You'll see this reflected in the high percentage attributed to recurring sales.

• Recurring revenue constituted 97% of QuidelOrtho Corporation's total revenue for the third quarter of 2025.
• Non-respiratory revenue for Q3 2025 was $588 million.
• Non-respiratory revenue, excluding the U.S. Donor Screening exit, grew 6% in constant currency for Q3 2025.

The growth drivers within this recurring base are what management is leaning on to offset the expected decline in COVID-19 testing. For instance, in Q3 2025, the Labs business revenue grew 5% as reported, and the Triage product line posted 7% growth. Also, the Immunohematology segment saw growth of 5% in that same quarter.

Here's a quick math look at how the major components are expected to stack up for the full year 2025:

Revenue Component	Projected FY2025 Amount/Range
Full-Year Total Reported Revenue Guidance	$2.68 billion to $2.74 billion
COVID-19 Testing Revenue Projection	$70 million to $100 million

Instrument Sales and Service Contracts

While the bulk of revenue is recurring consumables, the initial placement of instruments-like the VITROS platform-is key to securing that future consumable stream. Instrument sales and leases are the initial transaction that locks in the long-term consumable revenue. Service and maintenance contracts for these installed diagnostic systems are defintely bundled into the recurring revenue stream, supporting the 97% figure reported for Q3 2025. The company is also focused on new assay clearances, such as the VITROS high-sensitivity troponin assay, which is designed to drive future utilization.

The COVID-19 Revenue Normalization

The most significant change in the revenue profile is the expected drop in COVID-19 testing revenue. Management now projects COVID-19 revenue for the full year 2025 to be in the range of $70 million to $100 million. This compares to the prior year's figures, where Q3 2025 COVID-19 revenue was down 63% year-over-year, contributing to the overall revenue decline in that quarter. The company is clearly moving toward an endemic-level expectation for this revenue line.